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Endometrial carcinoma is the most common type of female genital tract malignancy. Although endometrial carcinoma is a low
grade curable malignancy, the condition ofthe disease can range fromexcellent prognosis withhigh curability toaggressive disease
with poor outcome. During the last 10 years many researches have provided some new valuable data of optimal treatments
for endometrial carcinoma. Progression in diagnostic imaging, radiation delivery systems, and systemic therapies potentially
can improve outcomes while minimizing morbidity. Firstly, total hysterectomy and bilateral salphingo-oophorectomy is the
primary operative procedure. Pelvic lymhadenectomy is performed in most centers on therapeutic and prognostic grounds and to
individualize adjuvant treatment. Women with endometrial carcinoma can be readily segregated intraoperatively into “low-risk”
and “high-risk” groups to better identify those women who will most likely beneﬁt from thorough lymphadenectomy. Secondly,
adjuvant therapies have been proposed for women with endometrial carcinoma postoperatively. Postoperative irradiation is used
to reduce pelvic and vaginal recurrences in high risk cases. Chemotherapy is emerging as an important treatment modality in
advanced endometrial carcinoma. Meanwhile the availability of new hormonal and biological agents presents new opportunities
for therapy.
1.Introduction
Endometrial carcinoma is the most common type of female
genital tract malignancy. It is estimated that 42,160 cases of
endometrial carcinoma were diagnosed in the United States
in 2008 and 7780 women would die from the disease [1].
Since the primary symptom is abnormal uterine bleeding
in postmenopausal women, most patients would have a
better chance of survival if diagnosed at an early stage of
the disease. However, there still remain a lot of challenges
in the clinical treatment of endometrial carcinoma. At the
diagnostic stage, the condition of the disease can range
from excellent prognosis with high curability to aggressive
disease with poor outcome. In this paper, our goals are to
discusscurrentchallengesinthemanagementofendometrial
carcinomaandtoprovideanoverviewofthenewapproaches
that would help overcome these challenges.
2.Pathological andBiologic Type
Pathological examination is the cornerstone in diagnos-
ing endometrial carcinoma. There are diﬀerent types
of endometrial carcinomas, as shown in Table 1.T h e
endometrioid tumors are further classiﬁed according to
the degree of morphological diﬀerentiation. As deﬁned by
the International Federation of Gynecology and Obstetrics
(FIGO), endometrioid carcinoma of grade 1 consists of well-
formed glands, with no more than 5% solid nonsquamous
areas (areas of squamous diﬀerentiation are not deemed
to be solid tumor growth). Carcinomas of grade 2 consist
of 6–50% and grade 3 consists of more than 50% solid
nonsquamous areas. The tumor is upgraded from grade 1 to
2, or from grade 2 to 3 if striking cytological atypia is found
[2].
It is considered that the diﬀerent molecular biology of
the diﬀerent histological type is probably related to diﬀerent
behavior and prognosis. With more understanding about
biologic behavior of endometrial carcinoma, we know that
histological grading is far from enough to evaluate degrees
of malignancy of endometrial carcinomas. Although about
80% of all endometrial carcinomas are of the endometrioid
type,severalsubtypesorvariantsofendometrioidcarcinoma
provide more valuable information for guiding therapy.
Most of all, special subtypes may be associated with higher2 Obstetrics and Gynecology International
Table 1:WHOhistologicalclassiﬁcationofendometrialcarcinoma.
Endometrioid adenocarcinoma
V a r i a n t s :w i t hs q u a m o u sd i ﬀerentiation
Villoglandular
Secretory
with ciliated cells
Other adenocarcinomas
Mucinous carcinoma
Serous carcinoma
Clear-cell carcinoma
Mixed carcinoma
Squamous-cell carcinoma
Transitional-cell carcinoma
Small-cell carcinoma
Undiﬀerentiated carcinoma
death rate, for example, uterine papillary serous tumors and
clear cell carcinoma. On the basis of their Pathological and
biologic features, endometrial carcinomas are classiﬁed into
2s u b t y p e s[ 2].
About 80% of all endometrial carcinomas are type I
carcinoma (endometrioid type), arise from atypical com-
plex hyperplasia, which seems to aﬀect mainly pre- and
perimenopausal women and presents with less myometrial
invasion, lower grade disease. The type I tends to arise in
the setting of prior estrogen stimulation because it is usually
estrogen receptor positive and associated with hyperestro-
genism [3, 4]. Other associated ﬁndings include late onset of
menopause, nulliparity, diabetes mellitus, and hypertension.
ThepatientswithTypeIendometrialcarcinomahaveabetter
prognosis since the lesion is limited to the uterus in 70% of
the cases; the 5-year survival rate of these patients is more
than 85%.
In contrast, type II tends to occur in elderly post-
menopausal women with high risk of relapse and metastatic
disease, often with aggressive histologies such as serous or
clear cell [3, 4]. Type II endometrial carcinomas appear to
be unrelated to high estrogen levels. These tumors are not
oestrogen driven and often develop in nonobese women.
Type II endometrial carcinomas appear to be associated
with endometrial atrophy; the histological type is either
poorly diﬀerentiated endometrioid or nonendometrioid. A
high proportion of tumors, even those with little or no
myometrialinvasion,haveextensiveextrauterinespreadwith
complete surgical staging. More than 60% of patients with
type II endometrial carcinoma present with advanced dis-
ease; 5-year survival is 43% for patients with stage III disease
and 3% for patients with stage IV disease. Without adjuvant
chemotherapy or vaginal brachytherapy, the recurrence rate
is 23% in patients with stage I disease [4].
The molecular basis for diﬀerent progression of these
two subtypes is still unknown. However, a lot of clinical
observations exhibited that gene alterations are speciﬁc for
carcinomas of types I and II, which supports a dualistic
modelofendometrialcarcinogenesis[5–10].TypeIendome-
trial carcinomas display a high incidence of alterations in
KRAS oncogene, PTEN tumor suppressor gene [5, 6, 11–
13], the β-catenin gene [14, 15], as well as defects in
mismatch repair that results in microsatellite instability
[10, 16]. In contrast, type II endometrial carcinomas are
more likely to be characterized by p53 mutation and
ERBB-2 (HER-2/neu) expression, and less commonly asso-
ciated with E-cadherin and widespread aneuploidy [17–
21]. However, there is some discrepancy in gene alterations
report between two types of endometrial carcinomas (i.e.,
BUB1, CCNB2, MYC, STK15, etc.) [22]. Wong et al.
performed an integrated, genome-wide analysis of gene
expression in endometrioid adenocarcinomas and compared
with normal endometrium controls. Supervised analysis
identiﬁed 15 genes signiﬁcantly upregulated and 132 genes
downregulated in endometrial carcinoma, as compared with
normal control. The gene expression proﬁles in endometrial
carcinoma were classiﬁed in mutually dependent 6 function
sets, resulting in 10 biological processes according to gene
ontology. The gene ontology analysis showed that endome-
trial carcinogenesis underwent complete down-regulation
of integrin binding and cell adhesion activity. Gene path-
way analysis revealed the interaction among the genes of
interest and its role in the endometrial carcinogenesis.
The results from this preliminary study highlight novel
molecular features of endometrioid endometrial carcinoma
[23].
Thesedataindicatedthatdistinctpatternsofgeneexpres-
sion characterize various histological types of endometrial
carcinoma.Anunderstandingofthemolecularheterogeneity
could potentially lead to better individualization of treat-
ment in the future. Although some inconsistencies between
single-gene and the whole-genomic approach have been
observed, gene-array studies should be useful to disentangle
molecular pathways and to identify potential targets for
molecular-based treatments.
3.DiagnosticApproach
Endometrial carcinoma presents with abnormal uterine
bleeding in 90% of patients. But other diseases could also
cause abnormal uterine bleeding such as endometrial hyper-
plasia, and endometrial polyps. Proper treatment requires
adequate preoperative work-up consisting of histopathol-
ogy conﬁrmation and imaging. The clinical approach to
postmenopausal bleeding requires prompt and eﬃcient
evaluation to exclude or diagnose carcinoma.
One of the most convenient methods of achieving this
is transvaginal ultrasound. Transvaginal ultrasonography
can be useful in the triage of patients in whom endome-
trial sampling was performed but tissue was insuﬃcient
for diagnosis. Endometrial thickness is the most valuable
parameter to prognosticate both endometrial carcinoma and
any endometrial pathology (sensitivities of 90% and 89%,
and speciﬁcities of 79% and 94% with optimal cutoﬀso f
9.6 and 7.7mm, resp.) [24]. The majority of these studies
reported that a thin (4-5mm) endometrial measurement
on transvaginal sonography can exclude malignancy in the
majority of postmenopausal women with vaginal bleed-
ing. This has a negative predictive value of 96% whenObstetrics and Gynecology International 3
the endometrial echo is 4mm thick, whereas an echo
>4mm indicates the need for a biopsy [25].
When scanning demonstrates the possibility of pathol-
ogy, outpatient hysteroscopy and biopsy are the gold stan-
dard for investigating the endometrial cavity [26]. Hys-
teroscopy, a signiﬁcantly more accurate diagnostic method
for the detection of endometrial pathology than transvaginal
ultrasonography (TVS), has better speciﬁcity and should
be considered for all patients with abnormal uterine bleed-
ing with an endometrial thickness of more than 4mm.
For women showing abnormal or suspicious lesions, it
is necessary to perform hysteroscopy with eye-directed
biopsy because some cases of endometrial carcinoma are
unlikely recognized by ultrasonography with an endometrial
thickness less than 4mm, the possibility of missing is 0.8%
[27, 28]. It can be stated that there is a high level of
concordance between ﬁndings of hysteroscopic studies and
the directed endometrial biopsy [29]. But it is a pity that
hysteroscopy is not warranted as a ﬁrst line investigation for
postmenopausal bleeding [30].
When the diagnosis is conﬁrmed histopathologically,
imaging is recommended to identify stages of the dis-
ease radiologically prior to surgery. The accuracy/sensi-
tivity/speciﬁcity of TVS, CT, and MRI in detecting deep
myometrial invasion were 89%/90%/88%, respectively. The
sensitivityandaccuracyofMRIindetectingdeepmyometrial
invasion were signiﬁcantly higher than those of TVS and CT
[25]. For diagnosis of deep myometrial inﬁltration, cervical
invasion, or both, MRI sensitivity and speciﬁcity were 56%
and 85%; 47% and 83%; and 67% and 77%, respectively.
However MRI has limited value in identifying patients with
endometrial carcinoma who are at risk of lymph node
metastasis [31].
Positron emission tomography (PET) is a new imaging
technology in detection of subclinical nodal disease. Several
investigators have demonstrated the value of PET in screen-
ing endometrial carcinomas [32, 33]. Recently, Signorelli et
al. reported that patient-based sensitivity, speciﬁcity, positive
predictive value, negative predictive value, and accuracy of
18F-FDG PET/CT for detection of nodal disease were 77.8%,
100.0%, 100.0%, 93.1%, and 94.4%, respectively. Nodal
lesion site-based sensitivity, speciﬁcity, positive predictive
value, negative predictive value and accuracy of 18F-FDG
PET/CT were 66.7%, 99.4%, 90.9%, 97.2%, and 96.8%,
respectively. It seems that 18F-FDG PET/CT is an accurate
method for the presurgical evaluation of pelvic nodes metas-
tases. High negative predictive value may be useful in select-
ing patients who only may beneﬁt from lymphadenectomy
in order to minimize operative and surgical complications
[34]. Kitajima and his colleagues compared the accuracy
of integrated 18F-FDG PET/CT with intravenous contrast
medium in detecting pelvic and paraaortic lymph node
metastasis in patients of uterine carcinoma with surgical and
histopathological ﬁndings used as the reference standard.
They found that FDG-PET is only moderately sensitive in
predicting lymph node metastasis preoperatively in patients
with endometrial carcinoma [35]. Horowitz has similar
conclusion about the sensitivity and speciﬁcity of FDG-PET
for detecting pelvic and paraaortic lymph node metastasis
in patients with uterine corpus carcinoma before surgical
staging.ThesensitivityandspeciﬁcityofFDG-PETwere60%
and 98%, respectively. A notable question is this imaging
modality should not replace lymphadenectomy, but may be
helpful for patients on whom lymphadenectomy cannot be,
or was not, performed [36].
4. Treatment Overview
The cornerstone of curative for patients with endometrial
carcinoma is surgical treatment, including complete hys-
terectomy, removal of remaining adnexal structures, and
appropriate surgical staging in patients considered at risk
for extrauterine disease. During the last 10 years interest
in endometrial carcinoma has increased considerably and
investigations into the following areas have increased our
understanding of how we could reduce the risk of acquiring
the disease and how we could best use the surgical and
nonsurgical treatments available to us:
optimal use of adjuvant radiotherapy;
eﬀect of hormonotherapy;
role of chemotherapy;
eﬀectiveness of lymphadenectomy;
genetic predisposition to the disease; and
inﬂuence of less common histotypes.
5. SurgicalTherapy
Treatmenthasremainedrelativelyunchangedoverthelast40
years relying principally on surgery to achieve cure. Survival
is heavily dependent on surgical stage, which is determined
by the classiﬁcation system adopted by the FIGO in 1988.
Thefoundationofprimarytreatmentishysterectomy,during
which nodal assessment and surgical staging oﬀer the
opportunity for the most accurate assessment/detection of
occult extrauterine malignancy in all women whose disease
appears clinically conﬁned to the uterus. Although these
tenets are universally acceptable, the integration and imple-
mentationoftheseconceptswhenperformingthe“properor
appropriate” surgical procedure remain contested.
6.SurgicalStaging
Surgical staging of endometrial carcinoma was ﬁrst rec-
ommended 20 years ago by the FIGO. The development
of surgical staging in the management of endometrial
carcinoma has arisen over the last several decades with
anticipated beneﬁts including prognostic information, tai-
loring of adjuvant treatment, and a possible therapeutic
eﬀect. Twenty years later, the FIGO Committee introduced
changes in the staging criteria [37]. Firstly, The FIGO
Committee recognized the favorable prognosis for both the
former Stage IA and IB patients and elected to merge these
substages. Furthermore, the ambiguity of deﬁning cervical
invasion, based on the involvement of the cervical mucosa
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Stage IIA with Stage I disease. Secondly, the Committee
eliminated the isolated positive peritoneal cytology criterion
from the new staging system presumably based on the uncer-
tain prognostic importance of isolated positive peritoneal
cytology. Thirdly, the Committee incorporated some tumor
characteristics (such as positive peritoneal cytology, invasion
of the adnexa or vagina, or uterine serosa) by subdividing
Stage IIIC patients into 2 diﬀerent risk categories based on
the presence (IIIC2) or absence (IIIC1) of metastatic disease
in the paraaortic area.
Recently, Mariani et al. focused on the examination
of paraaortic metastases relative to the inferior mesenteric
artery(IMA),andfoundthat77%ofpatientswithparaaortic
node involvement had metastases above the IMA, whereas
nodes in the ipsilateral paraaortic area below the IMA and
ipsilateral common iliac basin were declared negative in 60%
and 71%, respectively. In 25 patients with paraaortic node
metastases which gonadal veins were excised, 28% patients
had documented metastatic involvement of gonadal veins
or surrounding soft tissue. These data indicates the need
for systematic pelvic and paraaortic lymphadenectomy up to
the renal vessels including consideration of excision of the
gonadal veins [38].
7. Lymphadenectomy
As will be referred to shortly, there has been a vigorous
debateaboutthebeneﬁtsofpelvic(plusorminusparaaortic)
lymphadenectomy. Although the assessment of the pelvic
and paraaortic lymph nodes has been recommended since
1988, FIGO failed to deﬁne either the anatomical extent
of the lymphadenectomy or the number of lymph nodes
harvested to be considered adequate for the assessment of
pelvic and paraaortic node basins. This question is further
complicated when people try to assess the adequacy of
lymphadenectomy that was performed.
There is also lack of consensus on the extent of surgical
staging in endometrial carcinoma. Some authors suggest
performing complete pelvic and paraaortic lymphadenec-
tomy on all endometrial carcinoma patients because positive
lymph nodes (including isolated paraaortic lymph nodes)
are common in all grades [39]. It is reported that the
carcinoma related survival and the recurrence free sur-
vival were better with standard surgery plus lymphadenec-
tomy than with with adjuvant radiotherapy in treating
the endometrioid adenocarcinoma type at high risk [40].
Other studies have assessed readily discernible parameters
intraoperatively to identify patients having an extremely
low probability of lymphatic spread in order to minimize
under- and over-treatment [38, 41]. A recent report by
Mariani et al. showed that sixty-three (22%) of 281 patients
undergoing lymphadenectomy had lymph node metastases:
both pelvic and paraaortic in 51%, only pelvic in 33%,
and isolated to the paraaortic area in 16%. Furthermore,
77% of patients with paraaortic node involvement had
metastases above the inferior mesenteric artery. Conversely,
lymphadenectomy does not beneﬁt patients with grade
1 and 2 endometrioid lesions with myometrial invasion
50% and primary tumor diameter 2cm [38]. In the
most recently published prospective randomized trials that
aimed to test the therapeutic beneﬁt of lymphadenectomy,
B e n e d e t t iP a n i c ir e p o r t e dt h a tb o t he a r l ya n dl a t ep o s t o p e r a -
tive complications occurred more frequently in patients who
had received pelvic systematic lymphadenectomy. Although
systematic pelvic lymphadenectomy statistically signiﬁcantly
improved surgical staging, it did not increase disease-free or
overall survival rate [42].
Researchers are concerned about the results of ASTEC
surgical trial that showed no evidence of beneﬁt in terms of
overall or recurrence-free survival for pelvic lymphadenec-
tomy in women of early endometrial carcinoma [43]. How-
ever, Amant et al. argued that there are several reasons why
the ASTEC trial did not show improved overall survival with
routine lymphadenectomy [44]. First, the number of lymph
nodes resected was insuﬃcient in many patients. Second,
the high rate of inclusion of low-risk patients and the low
number of lymph nodes removed are the reasons for the low
rate of involved lymph nodes seen in the lymphadenectomy
group. Third, the study group did not assess the paraaortic
nodes. Fourth, the ASTEC trial was too small to detect an
o v e r a l ls u r v i v a ld i ﬀerence because the expected proportion
of isolated pelvic lymph-node recurrences is as low as 2-3%
in early endometrial carcinoma.
Without clear standard recommendations, surgical stag-
ingwillcontinuetobeaconfusingtopic,withnoappropriate
quality control. There are still many unanswered questions.
Arethereacriticalminimumnumberofnodesthatshouldbe
resected?Dotheparaaorticnodesalwaysneedtoberesected?
Should the histologic type of uterine carcinoma determine
the extent of lymphadenectomy? Do the modern robotic-
assisted or laparoscopic approaches provide surgeons ade-
quateexposuretoperformsuﬃcientlymphadenectomy?The
ideal surgical staging for endometrial carcinoma remains a
subjectofactivedebate.Wearehopingthatmoreprospective
randomized trials will solve them.
8.Laparoscopy
The standard surgical surgery of endometrial carcinomas
includes total hysterectomy, bilateral salpingo-oophorecto-
my, and lymphoidectomy. However, the application of
laparoscopy in the management of gynecologic malignancy
has received much attention and given rise to considerable
debate. During the past few years, several investigators
have demonstrated that total or vaginally-assisted laparo-
scopic hysterectomy, associated with laparoscopic pelvic
lymphadenectomy, represents a valid alternative to open
surgery [45–48]. The potential health gain of performing
a laparoscopic hysterectomy instead of an abdominal hys-
terectomyinpatientswithearlystageendometrialcarcinoma
is expected in lower rate of intraoperative complications,
less blood loss; lower transfusion rate and haemoglobin
decrease, shorter hospital stay, as well as a faster return of
bowel activity and quicker return to activities in daily life.
Nevertheless, laparoscopic hysterectomy does not seem to
modify the disease-free survival and the overall survival,
laparoscopic approach is an eﬀective procedure for treating
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trials and long-term follow-up at various medical centers are
necessary to evaluate the overall oncologic outcomes of this
procedure.
9. Radiotherapy
Due to the diﬃculty in detecting cervical involvement
preoperatively, treatment paradigms for stage II endometrial
carcinoma often call for adjuvant radiotherapy postoper-
atively [52]. The debate regarding whether postoperative
radiotherapy could improve survivalhas been fueled by mul-
tiple retrospective studies which have presented conﬂicting
conclusions.
Several studies suggested that survival rate increases
if a surgery is performed in conjunction with adjuvant
pelvic radiotherapy, external beam radiotherapy (EBRT)
or brachytherapy (BT). For high-risk disease, the standard
care has always been pelvic radiotherapy. Clearly, there are
advantages as shown in meta-analyses and by the Cochrane
group [53, 54]. In the Gynecologic Oncology Group’s
prospective evaluation of adjuvant radiation, which included
patients with occult stage II tumors, radiation decreased the
risk of pelvic recurrence [55]. In a report of 162 stage II
endometrialcarcinomapatients,Cohnetal.notedthatthe5-
year disease-free survival was improved (94% versus 76%) in
patients who underwent radical hysterectomy [52]. Likewise,
the studies by Rossi teams came to similar conclusions. They
found that women with Stage IIIC endometrial carcinoma
receivingadjuvantEBRTandEBRT/BThadimprovedoverall
survival compared with patients receiving no additional
radiotherapy. When direct extension of the primary tumor
was present, the addition of BT to EBRT was even more ben-
eﬁcial [56]. Up to date, Wright and his colleagues examined
1577 women with stage II endometrial adenocarcinoma and
analyzed the role of radical hysterectomy and radiation in
management of endometrial adenocarcinoma. They found
that women who did not receive radiation were 48% more
likely to die from their tumors. The beneﬁt of adjuvant
radiation is most pronounced in women with high-risk
pathologic features who underwent radical hysterectomy
[57].
In contrast, other investigators have been unable to show
a survival beneﬁt based on the type of surgical procedure
performed. In the paper by Kong, there is undoubtedly a
beneﬁt in local control when adjuvant pelvic radiotherapy
is given but again no survival advantage. This is further
supported by a presentation at ECCO 2007 from Cornes and
Johnson in which they showed that there is up to a 10%
survival advantage for patients with IC G3 tumors treated
with pelvic radiotherapy [58]. They have also shown that
for low-risk patients adjuvant EBRT is probably detrimental
whilst for intermediate-risk patients although there may be
a small beneﬁt for some patients, this is oﬀset by additional
morbidity leading to an overall neutral eﬀect. There are also
two papers looking at data from the Survival, Epidemiology,
and End Results (SEER) database [59, 60]. Both Lee et
al. and Chan et al. analyzed the SEER data and showed
that patients with high-grade IC G3 tumors appeared to
beneﬁt but failed to show any beneﬁt to other patients. The
data from a prospective, multicenter randomized trial of
645 evaluable low-risk endometrial carcinoma patients was
showed that the impact of postoperative brachytherapy on
even the locoregional recurrence rate seems to be limited in
patients with low-risk endometrial carcinoma. The overall
recurrence rate and survival were similar in postoperative
vaginal irradiation and surgery alone groups [61].
The fresh data of ASTEC/EN.5 randomized trials was
published recently. There was no evidence that overall
survival with external beam radiotherapy was better than
observation. Combined data from ASTEC and EN.5 in a
meta-analysis of trials conﬁrmed that there was no beneﬁt
in terms of overall survival (hazard ratio 1.04; 95% CI
0.84–1.29) and can reliably exclude an absolute beneﬁt
of external beam radiotherapy at 5 years of more than
3%. Interpretation adjuvant external beam radiotherapy
cannot be recommended as part of routine treatment
for women with intermediate-risk or high-risk early-stage
endometrial carcinoma with the aim of improving survival
[62]. Meanwhile, we should notice that adjuvant external
beam radiotherapy did result in a small reduction in isolated
local recurrence, but this analysis only included women
who had local recurrence alone, ignoring 65% of women
who had local and distant recurrence at the same time, or
distant recurrence alone. The small reduction in isolated
local recurrence does not translate into an eﬀect on overall
or recurrence-free survival.
Up to this point, it was emerging that patients with low-
risk disease do not need any adjuvant treatment and can
be treated by surgery and careful follow up. Patients with
intermediate-risk disease are more problematic and may
still be treated with external beam radiotherapy. Although
the majority of retrospective data has not demonstrated a
beneﬁt for radiation, it has been suggested that women who
undergo simple hysterectomy and are found with cervical
disease may beneﬁt from radiotherapy [63]. Feltmate et
al. reported excellent outcomes in a series of 65 patients
with stage II endometrial carcinoma, the majority of whom
were treated surgically and followed by adjuvant radiation.
In their cohort, 5-year disease-speciﬁc survival was 93%
with recurrences in 15% [64]. Among 203 subjects with
endometrial carcinoma, Sartori et al. noted a statistically
signiﬁcant improvement in 5-year survival from 74% with
simple hysterectomy to 94% with a radical procedure [65].
Some clinical trials investigated the optimal of radio-
therapy mode. It is considered that brachytherapy is a more
convenient treatment than external beam radiotherapy and
might be associated with less toxicity. In the PORTEC1-
trial, the 5-year risk of vaginal and pelvic recurrence for
high- intermediate risk patients was 19% without further
treatment, compared to 5% after EBRT. Since most recur-
rences were located in the upper vagina, Phase II trials
suggested vaginal brachytherapy (VBT) to be as eﬀective as
EBRT. PORTEC-2 is the ﬁrst randomized trial comparing
the eﬃcacy of VBT and EBRT to determine which treatment
provides optimal local control with best quality of life.
The data suggested that vaginal brachytherapy is eﬀective
in preventing vaginal recurrence. Despite the slightly but
signiﬁcantly increased pelvic failure rate in the VBT arm,6 Obstetrics and Gynecology International
rates of distant metastases, OS, and RFS were similar. As
indicated by the patient survey on quality of life after
treatment, VBT was shown to be better than EBRT, VBT
should be the treatment of choice for patients with high-
intermediate risk endometrial carcinoma [66]. First results
of the randomized PORTEC-2 trial are evaluation about
quality-of-life (QOL) after pelvic radiotherapy or vaginal
brachytherapy for endometrial carcinoma. Patients in the
VBT group reported better social functioning (P<. 002)
and lower symptom scores for diarrhea, fecal leakage, the
need to stay close to the toilet, and limitation in daily
activities because of bowel symptoms (P<. 001). Vaginal
brachytherapy provides a better quality of life than external-
beam radiotherapy for Endometrial Carcinoma, and should
be the preferred treatment from a quality of life perspective
[67].
Nevertheless, the data is important and add to our
understanding of the optimal management of endometrial
carcinoma. Data from these data banks and the Cochrane
reviews may help to address the question of which is the
optimal treatment for this group. A further approach is to
withhold radiation in the intermediate-risk group and oﬀer
careful surveillance and use salvage radiotherapy for relapses
conﬁned to vagina or vault. In the meantime we should
consider that either immediate external beam radiotherapy
or a watch and see policy with salvage radiation should be
the standard approach.
10. Chemotherapy
Chemotherapy is emerging as an important treatment
modality in advanced endometrial carcinoma. The use of
neoadjuvant chemotherapy resulted in a high rate (80%)
of optimal interval debulking surgery for the treatment of
endometrial carcinoma with transperitoneal spread [68].
GOG 122 was the ﬁrst randomized study to demonstrate
a survival advantage with chemotherapy in advanced stage
endometrial carcinoma [69]. At 60 months, 50% of patients
received doxorubicin and cisplatin chemotherapy were pre-
dicted to be alive and disease-free when adjusting for
stage compared with 38% of patients who had whole-
abdominal irradiation. The data from GOG 122 showed
that combination chemotherapy had a survival advantage
over whole abdominal radiotherapy in Stage III and IV
endometrial carcinoma.
There are several studies focused on the toxicity, tolera-
bility, and feasibility of delivering combination chemother-
apy with subsequent radiation therapy to women with
advanced endometrial carcinoma, and evaluate the long-
term bowel toxicity. It is notable that GOG 122 study had
an extremely high toxicity rate from chemotherapy (68%
Grade 4 hematologic toxicity), including 8 treatment-related
deaths.Itisapparentthatcisplatinand/ordoxorubicin-based
regimens are associated with unfavorable rates of toxicity
[69]. A Phase I GOG study by Soper et al. indicates that
treatments comprised of whole abdomenopelvic radiation
with concomitant weekly cisplatin, followed by doxorubicin
and cisplatin chemotherapy, had prohibitive toxicity and
did not undergo further evaluation [70]. Bruzzone et al.
reported a series of 45 women who received cisplatin and
cyclophosphamide followed by radiotherapy, in which 10
women (22%) completed 3 cycles or less [71]. Duska et
al. reported a pilot study for advanced stage disease, which
included 3 cycles of paclitaxel, doxorubicin, and carboplatin,
followed by radiotherapy [72]. All patients required G-CSF
support,but50%stillexperiencedGrade3or4acutetoxicity.
In RTOG 9708, in which 4 cycles of cisplatin and paclitaxel
were administered after completion of radiotherapy, acute
Grade3/4toxicitywasgreaterthan80%[73].Incomparison,
Lupe et al. used the combined modality protocol comprised
ofcarboplatinandpaclitaxelwithinvolvedﬁeldradiotherapy
hadamuchloweracutetoxicityrate,andthecompliancerate
was very high [74].
Meanwhile, the use of chemotherapy alone has been
associated with high rates of pelvic relapse, ranging from
18%to47%[69,75].Recently,Takeshimaetal.reportedwith
postoperative adjuvant chemotherapy, recurrences occurred
predominantly at distant sites in the absence of pelvic
radiationinsurgicallystagedgrade3endometrialcarcinoma.
Estimated 5-year disease-free survival rates were 89.8% for
patients with surgical stage I-II disease, 78.6% for those
with surgical stage III disease, and 87.3% overall [76].
There is an emerging consensus that chemotherapy may be
insuﬃcient for reducing the risk of pelvic relapse although
it appears to be an important component of treatment.
Sovak et al. reported a pelvic relapse rate of 44% in patients
with Stage III and IV disease who received 6 cycles of
adjuvant carboplatin and paclitaxel, of whom only 5 (10%)
also received adjuvant pelvic radiotherapy [77]. In RTOG
9708, the pelvic relapse rate was only 2%. It suggested
that the addition of radiation to chemotherapy does appear
to be associated with a lower rate of pelvic relapse [73].
However, in that study, 23% had Stage I and 16% had
Stage II disease. The low rate of pelvic relapse may be
partly attributed to the more favorable stage distribution.
Alvarez Secord et al. published a large retrospective study
of 356 Stage III and IV patients treated with radiation
alone (48%), chemotherapy alone (29%), and combined
modality therapy (23%) [78]. After adjusting for stage,
age, grade, and debulking status, the hazard ratios (HR)
for overall survival were 1.6 (95% CI 0.88–2.89) and
2.0 (95% CI 1.17–3.48) for chemotherapy and radiation
alone, respectively, compared to combined modality therapy.
Matsuura et al. reported most recently that combined
treatment with radiotherapy/chemotherapy was associated
with a better survival rate than chemotherapy alone (78%
versus 62%, resp.). In Stage IIIc endometrial carcinoma,
the combined use of radiotherapy and chemotherapy could
reduce pelvic recurrence (33.3% and 7.1%, resp.) and was
associated with a better survival rate than chemotherapy
alone(78% versus62%, resp.) [79].Basedonthisconcurrent
carboplatin/paclitaxel and intravaginal radiation in surgical
stage I-II serous endometrial carcinoma study, surgical
staging followed by involved-ﬁeld radiotherapy and carbo-
platin/paclitaxel is well tolerated and eﬀective in stage I-II
serous endometrial carcinoma [80]. Conﬁrmation of these
results on a larger number of patients with longer follow-up
is still needed.Obstetrics and Gynecology International 7
What is the optimized chemotherapy regimen is still
a subject of debate. Historically, the treatments used have
been a combination of a platinum and anthracycline, usually
cisplatin and doxorubicin (AP), but this can be quite a
toxic regime and is often poorly tolerated, therefore it is
not ideal for combining with radiation therapy. Adding
paclitaxel (TAP) usually needs growth factors to support
the administration. Hellenic Co-operative Oncology Group
(HeCOG) studied the drug regimen comprised paclitaxel,
topotecan, and carboplatin in metastatic endometrial car-
cinoma. With G-CSF support, the drug regimen appears
active with acceptable toxicity in patients with metastatic or
recurrent carcinoma of the endometrium [81]. In relapsed
disease, the GOG are currently evaluating TAP versus TC
[82]. In addition, the optimal regimen remains to be deﬁned
as all of them (doxorubicin/cisplatin-AP, cyclophosphamide/
doxorubicin/cisplatin-CAP, paclitaxel/carboplatin-TC, and
paclitaxel/doxorubicin/cisplatin-TAP)causesigniﬁcanttoxi-
city. Although randomized evidence is limited, the combina-
tionofcarboplatinandpaclitaxelhasbeencommonlyusedin
advanced endometrial carcinoma because of its manageable
toxicity and excellent response rates (64–78%) [77, 83–88].
McMeekin et al. studied the maximum tolerated dose and
feasibility of weekly cisplatin and paclitaxel chemotherapy
administered concurrently with whole abdominal radiation
therapy in women with high-risk endometrial carcinoma.
A regimen of cisplatin 25mg/m2 and paclitaxel 20mg/m2
weekly with whole abdominal radiation therapy was deter-
mined to be feasible, but is associated with moderate acute
and chronic gastrointestinal toxicity [89].
Further investigations are required to deﬁne the sub-
group of patients who beneﬁt from postoperative adjuvant
chemotherapy. Two randomized clinical trials are in progress
in order to obtain available evidence which can help
clinicians make wise decisions on treatment options, such
as adjuvant chemotherapy of patients with high-risk stage
I and II, as well as stage IIIA endometrial carcinoma. GOG
209 is an ongoing study randomizing women with Stage
III or IV endometrial carcinoma to either doxorubicin,
cisplatin,paclitaxelwithG-CSF,orcarboplatinandpaclitaxel.
Additionally, PORTEC 3 is an ongoing randomized Phase
III trial comparing concurrent chemoradiation and adjuvant
chemotherapy (4 cycles of carboplatin and paclitaxel) versus
pelvic radiation alone in high risk and advanced stage
disease. This study is timely and necessary to determine
whether radiotherapy or chemotherapy improves overall
survival and failure-free survival, compare the rates of severe
(grades3and4)treatment-relatedtoxicity,pelvicanddistant
recurrence, and evaluate quality of life of patients with high-
risk and advanced stage endometrial carcinoma.
11. Functional Preservation
Although the median age of patients with endometrial
carcinoma is in the early 60s, approximately 5% of patients
are younger than age 40 when diagnosed. In the presence
of early staged endometrial carcinoma, most have favorable
outcomes, thus their quality of life after treatment is as
important a consideration as a cure of carcinoma. This
issue is especially imperative when endometrial carcinoma
is encountered in younger or reproductive ages when the
aﬄicted woman has not achieved her fertility function.
Despite being a critical issue, there are only a few studies
with deﬁnite treatment guidelines or any evidence-based
recommendations concerning conservative treatment for
endometrial carcinoma.
Since early 1980s, there have been several reports
on conservative treatment with progestins for early-stage
endometrial carcinoma in young women. Most of them were
smallseriesandretrospectivestudiesfromsingleinstitutions.
Response rates and recurrence rates varied (i.e., the response
rate for endometrial carcinoma and atypical endometrial
hyperplasia ranged from 57% to 76% and from 83% to
92%, respectively, and the recurrence rate ranged from
11% to 50%) [90–96]. Such variations were probably due
to the diﬀerences in drugs used, dosage, and duration of
treatment. Daily doses of megestrol acetate ranged between
10 and 400mg, and that of medroxyprogesterone acetate
(MPA) ranged between 200mg and 800mg. Nevertheless,
there have been no prospective trials to investigate the
optimal dosage, duration of treatment, curative rate of MPA
treatment, or pregnancy rate after this therapy in young
women with endometrial carcinoma and atypical endome-
trial hyperplasia. Therefore, Ushijima et al. conducted a
multicenter, prospective phase II study on MPA treatment.
Their prospective study conducted to clarify the accurate
complete response (CR) rate of treatment with MPA at
a ﬁxed dose of 600mg/d for 26 weeks, has demonstrated
that the CR rate for endometrial carcinoma and atypical
endometrial hyperplasia was 55% and 82%, respectively, and
the recurrence rate was 57% and 38%, respectively [97]. In
anotherprospectivemulticentricprospectivestudy,Ushijima
et al. evaluated the eﬃcacy of fertility-sparing treatment by
MPA for endometrial carcinoma and atypical endometrial
hyperplasia. Complete response was found in 44% in
endometrial carcinoma and 82% in atypical endometrial
hyperplasia. 9 pregnancies and 4 normal deliveries have been
recorded after MPA therapy. Twelve recurrences were found
in 30 complete response patients (40%) between 7 to 22
months. Data showed that even in the complete response
patients, close follow-up is required because of their high
recurrence rate [98]. Recently, Signorelli et al. conducted
a prospective study of conservative treatment in 21 young
nulliparous women with grade G1 endometrial carcinoma
stage IA or atypical complex hyperplasia. All were treated
with a low-dose cyclic natural progestin therapy (200mg/day
from day 14–25) and encouraged to attempt pregnancy
immediately. Overall response rate to progestin therapy was
57%. Nine women conceived spontaneously (43%) and
8 women with persistent disease or partial response to
hormonal treatment. Three additional complete responses
were observed after delivery [99].
A largely unanswered question is the safety of ovarian
preservation in young women with endometrial carcinoma.
First, estrogen production from the ovaries may stimu-
late microscopic foci of residual endometrial carcinoma.
Although vitro data [100] has suggested that estrogen
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upregulatestheexpressionofestrogenreceptors,thisconcern
has not been observed clinically so far. Several reports
examined the use of estrogen replacement therapy in
postmenopausal women with endometrial carcinoma. Yet,
these studies have not demonstrated any increase in the
risk of recurrence or death in women receiving estrogen
replacement [101–103]. The new data published by Korean
Gynecologic Oncology Group (KGOG) in 2009 suggest
that ovarian preservation does not adversely impact the
recurrence of early stage endometrial carcinoma [103].
The most inﬂuential report was a prospective trial of
estrogen replacement therapy in more than 1,200 women
with endometrial carcinoma conducted by the Gynecologic
Oncology Group. Although the prospective trial was closed
early, the absolute recurrence rate was only 2.1% (HR 1.27;
95% CI, and 0.92 to 1.77) [101]. The ﬁndings from these
studies, as well as the data from Wright group, suggest that
the risk of estrogenic stimulation of residual endometrial
carcinoma is quite low, particularly in women with early-
stage, low-risk lesions. The second potential risk of ovarian
conservation is the presence of a coexisting synchronous
primary tumor within the ovaries. Synchronous primary
tumors of the endometrium and ovary are reported in
approximately 5% of women with endometrial carcinoma
[104]. However, among young women with endometrial
carcinoma, the incidence of coexisting ovarian tumors is
increased and has been reported with a range from 5% to
29% [104–107].
Althoughmanystudieshaveexaminedtheriskofovarian
metastases in young women with endometrial carcinoma,
there are no data to describe the safety of ovarian con-
servation. In 2009, Wright ﬁrstly reported that ovarian
preservation is safe in young women with early-stage, low-
grade endometrial carcinoma [108]. Their ﬁndings are
notable in that ovarian preservation in premenopausal
women with early-stage, low-grade endometrial carcinoma
may be safe and not associated with an increased risk of
carcinoma related mortality. Although the survival estimates
suggest that ovarian conservation does not negatively impact
outcome, it should be recognized that ovarian preservation
may be associated with a two-fold or greater increase in
mortality. Given the potential consequences of surgical
menopause, furtherresearchto examine the safety of ovarian
conservation for young women with early-stage endometrial
carcinoma is clearly warranted. At present, the long-term
risks and beneﬁts of ovarian preservation should be carefully
discussed with young women with endometrial carcinoma
before hysterectomy.
12.FertilitySparing
Although there is no known fertility-sparing surgical option
for women with endometrial carcinoma, selected young
patients of childbearing age with apparent early endometrial
carcinoma who wish to preserve fertility may consider
treatment with progestin therapy rather than surgery. If
such treatment is contemplated, it is recommended that
a thorough hysteroscopy and curettage be performed to
rule out a worse lesion prior to initiation. A review of
the literature indicates 101 patients with a median age of
29 years who were treated with progestin therapy rather
than deﬁnitive surgery subsequently had 56 children [91].
Additionally, Gershenson et al. provided indirect evidence to
support the recent concept of using the fertility-sparing or
conservative surgery or therapy for malignancies in women
that the use of conservative modalities can be applied in
the management of endometrial carcinomas because there
are many reports showing that endometrial carcinomas can
be treated with a simple diagnostic dilatation and curettage
followed by some potent hormone therapy, including a
progestin agent, in highly selected young women who would
like to preserve their fertility potential [109].
Recently, there have been a number of reports of women
with uterine endometrial carcinoma who became pregnant
and gave birth after the administration of medroxypro-
gesterone acetate (MPA) [93, 110–114]. Meanwhile subse-
quently assisted reproductive techniques such as transfer of
embryos with intracytoplasmic sperm injection (ICSI) and
preimplantation genetic diagnosis (PGD) may be valuable to
achieve immediate pregnancy [115–117].
Gadducci et al. reviewed the related literature and
conﬁrmed that approximately three fourths of the women
achieve a histologically documented complete response,
with a mean response time of 12 weeks, but about one
third of these subsequently developed a recurrence after a
mean time of 20 months. Following high dose progestin
therapy and conﬁrmation of the regression of carcinoma,
the patient might attempt to conceive spontaneously. How-
ever, assisted reproduction techniques might increase the
likelihood of pregnancy and decrease the time interval to
conception. Several successful pregnancies have occurred
after a fertility-sparing treatment of endometrial atypical
hyperplasia or endometrial carcinoma, more frequently with
assistedreproductivetechnologies.Theimplementationofin
vitro fertilisation techniques not only increases the chance
of conception, but it may also decrease the interval to
conception [118]. However, despite the achievements of
these studies on fertility-sparing treatments, there are no
deﬁnite treatment guidelines or any evidence-based recom-
mendations and many questions still remain unanswered
regarding the selection of patients. Nevertheless, the optimal
dose or duration and curative rate of MPA therapy in
endometrialcarcinomaandatypicalendometrialhyperplasia
in young women are still uncertain.
Itisvitaltochooseappropriatepatientswithendometrial
carcinoma to adopt ovarian preservation and fertility-
sparing treatment. The best candidates for progestin therapy
are women who have a relative hyperestrogenic state, which
is thought to cause the malignancy. Indeed, some patients
would not chose fertility-sparing treatment given the lack of
dataononcologicsafety.Fertility-sparingtreatmentsaresuc-
cessfully used; however, these treatments can be oﬀered only
to a limited number of patients which meet the pathologic
criteria for a conservative approach [119]. The indications
for conservative treatment include the patient’s desire to
preserve fertility, no medical history of thrombosis, and
no abnormal levels of hemostasis, a histologic diagnosis of
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curettage, no myometrial invasion or extrauterine spread of
the disease observed by MRI, and hysteroscopy and total
endometrial curettage must be repeated after 4–6 weeks
of additional MPA therapy. Additionally, the expression of
receptor for progesterone receptor (PR), PTEN gene, DNA
mismatch repair gene MLH1 and phospho-AKT on tissue
specimens may be useful for selecting patients ﬁt for a
conservative management [118, 120].
The opportunity of a demolitive surgery after delivery
or after childbearing being no longer required is still a
debatedissue.Largemulticentertrialsarestronglywarranted
to better deﬁne the selection criteria for a conservative
treatment, endocrine regimen of choice, the optimal dosing,
the duration of treatment and follow-up protocols. Until
now, the long-term outcome of children in utero exposed
to oncological treatment modalities is poorly documented.
Delivery should be postponed preferably until after a gesta-
tional age of 35 weeks. Further research including interna-
tional registries for gynecologic carcinoma in pregnancy is
urgently needed. The gathering of both available literature
and personal experience suggested models for treatment of
gynecologic carcinoma in pregnancy [121]. In any case, the
patient should be accurately informed about the relatively
high recurrence rates after complete response to hormone
treatment and expectations for pregnancy.
13. Biomarker andTargeted Therapy
As previously stated, distinct molecular changes are asso-
ciated with two subtypes, and these distinct molecular
alterationsalsounderscoreprognosticdiﬀerences.Therefore,
active researches are enthusiastic about novel screening
approaches that emerged from epigenetics, proteomics, and
genomics in endometrial carcinoma. It is hopeful that the
u s eo ft a r g e t e dt h e r a p i e sw i l li m p r o v et h eo u t c o m ef o r
endometrial carcinoma.
Nowadays, several novel tumor markers with increased
sensitivity and speciﬁcity for endometrial carcinoma have
been identiﬁed and are considered to help monitor response
to therapy and to detect recurrent disease. These potential
molecular biomarkers include HE4, CA125, Cyr61, p21, p53,
Cathepsin-B, MMR, and ERR[alpha] progesterone receptor
(PR)-A, which are estimated to contain potential value as
prognostic factors for patients with endometrioid carcinoma
[122–128]. Additionally, Bidus et al. reported two cell cycle
checkpoint genes, CDC2, MAD2L1, and The ZIC2 zinc
ﬁnger gene were associated with lymph node metastasis
in endometrial carcinomas [129]. Currently, these tumor
makers are utilized in this role with limited value. Further
investigation in the role of biomarker for early detection of
recurrent endometrial carcinoma and monitoring response
to therapy is warranted. Gene expression proﬁling of the
primary tumors in patients with endometrioid endometrial
carcinomas seems promising for identifying genes associated
with lymph node metastasis. Future studies should address
whether the status of nodal metastasis can be determined
fromtheexpressionproﬁlesofpreoperativetissuespecimens.
With the progress of advanced gene techniques, it has
become possible to identify potential molecular markers
of endometrial carcinoma for its diagnosis, prognosis and
therapy by global gene expression proﬁling. It may provide
a foundation for the development of new diagnostic and
prognostic markers and type-speciﬁc therapies against this
common female genital malignant disease. Such procedure
allowed us to give shape to preliminary gene expression
proﬁle typical for neoplastic tissue and to estimate protein
expression of the most signiﬁcant predictors of neoplastic
transformation. Comparison of obtained data with tumor
grade can reveal new markers of endometrial carcinoma
useful in routine diagnostic procedures [23, 130].
Genes related to the endometrial carcinoma progres-
sion and metastasis can be identiﬁed by diﬀerential gene
expression proﬁle with cDNA microarray and high-risk
endometrial carcinoma may be distinguished before surgery
by hierarchical cluster analysis [131]. Similarly, the dys-
regulation of these miRNAs appeared to be involved in
the progression of endometrial carcinoma [132]. Therefore,
some researchers suggested that the cDNA and miRNAs
microarray techniques may be feasible to generate gene
expression proﬁles of endometrial carcinoma. Classiﬁcation
based on gene expression patterns may be more accurate
than histological grade and FIGO stage classiﬁcation in
predicting the prognosis of tumors [133]. Further extended
and functional studies of these new approaches are required
to conﬁrm the potential use of them in the endometrial
carcinomas.
With the applications of the target gene therapy, some
valuable research had carried in advanced endometrial
carcinoma. Since the year 2000, in advanced endometrial
carcinoma, the GOG has conducted phase II trials with sev-
eral molecular targeting agents including imatinib (Gleevec),
trastuzumab (Herceptin), and geﬁtinib (Iressa) as single
agents with negligible evidence of activity. The GOG does
have active trials of chemotherapy with a molecular targeting
agent such as bevacizumab (Avastin) in GOG 218, but
there are no randomized molecular targeting agent trials
in advanced endometrial carcinoma [134]. Some genes
relatedwithendometrialcarcinomaprognosishavebecomea
hopeful target for therapies in endometrial carcinoma, these
targeting genes include mTOR inhibitors, EGFR tyrosine
kinase inhibitors (erlotinib), and monoclonal antibodies to
Her-2/neu (trastuzumab) [135–138]. However, acceptance
of genetic consultation and testing is surprisingly low and
deserves further investigation. For example, it is hypothe-
sized that the HER-2/neu receptor could be used for targeted
therapy in recurrent endometrial carcinoma. In a clinical
trial, trastuzumab was of little clinical value in two cases of
recurrent type II endometrial carcinoma based on the lack
of response and changes in tumor biology [139]. In another
trial, a multinomial design two-stage phase II study was per-
formedtoevaluatesingle-agentactivityoferlotinib,anorally
active, selective inhibitor of EGFR tyrosine kinase activity,
in women who had advanced endometrial carcinoma with
recurrent or metastatic disease, and were chemotherapy
naive and received up to one line of prior hormonal therapy.
The data showed that erlotinib is well tolerated with an
overall objective response rate of 12.5% [136]. These reports
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treatment in endometrial carcinoma. Yet, researchers still
have a long way to go in order to reach the goal of applying
the targeting gene therapy in clinical practice.
14. PreventionandSurveillance
In the follow-up of endometrial carcinoma patients, pain
was the most common complaint in patients with recurrent
disease, followed by vaginal bleeding, general malaise, loss
of weight and intestinal complaints. With the evidence from
randomized clinical trials we can conclude that a follow-
up program in the ﬁrst three years after primary treatment
of endometrial carcinoma is helpful in detecting recurrent
disease.
In 2007, van Wijk et al., evaluated their clinical data of
patients with recurrent endometrial carcinoma treated in
the Erasmus Medical Centre in Rotterdam over a 20-year
period [140]. He reported that patients with screen-detected
recurrences had a 5-year survival rate of 62%. Patients with
interval screening recurrences or recurrences detected by
chance had a 5-year survival rate of 47%. Evaluating the
patients with an endometrioid type of tumor separately, the
5-year survival rate for patients screen-detected recurrences
is 68% and for patients with interval screening recurrences
is 51% [140]. The reported median intervals to local and
distant recurrent disease are consistent with those reported
in the literatures [141, 142].
Tjalma et al. published an overview of 11 retrospective
studies (evaluating 2866 patients) on routine follow-up
of endometrial carcinoma. In these studies symptomatic
recurrences ranged between 41% and 81% (mean 65%) of
all recurrences [143]. Retrospective data from both Agboola
group and Tjalma group suggest that there is no diﬀerence
in survival between symptomatic and asymptomatic recur-
rences, or between women with recurrences detected during
routine follow up visits and those with recurrences detected
during the interval between routine visits [143, 144]. Fur-
thermore, there is no economic or clinical justiﬁcation for
the routine use of the Pap smear and systematic radiography
in the follow-up of patients with endometrial carcinoma
[144, 145]. Centers advocating surveillance should focus on
thedetectionofpotentiallycurablevaginalrecurrences,since
isolated vaginal-vault recurrence of endometrial carcinoma
is curable in up to 87% of cases, in patients previously not
exposed to radiation [146].
Tjalma et al. pointed out that because of a diﬀerence in
survival between isolated vaginal recurrence and nonvaginal
recurrences, 5-year survival, respectively 50% and 6%, it is
important to identify isolated vaginal recurrences early. As
the sensitivity of routine follow-up schemes appears very
low, tailored follow-up protocols based on high risk and low
risk for recurrence are suggested [143]. Low risk patients
are generally deﬁned as patients with adenocarcinoma IA
g r a d e1o r2o rI Bg r a d e1 ,w i t har e c u r r e n c er a t eo fj u s t
under 4%, whereas high risk patients have a recurrence rate
of around 23% [147]. Salvesen et al. found a low risk group,
with FIGO Stage IA/IB or patient age below 60 years at
primary operation was identiﬁed in multivariate recurrence-
free survival analysis. No asymptomatic recurrences were
found in this group. Therefore, they concluded that low risk
patients should be considered for less frequent follow-up
[141]. However, van Wijk et al. reported of ﬁve low risk
patients with recurrent disease, only one patient, suﬀering
from distant recurrent disease, was symptomatic. Without
a follow-up program for patients with low-risk endometrial
carcinoma, recurrent disease would only have been detected
aftersymptomshaddevelopedinfouroftheseﬁvepatients.It
was discussed that there is no reason to use diﬀerent follow-
up scheme for these patients, despite our low number of
patients with low risk disease. Improving patient education
so that early symptoms of recurrence are reported appears
eminently sensible, but may serve also to heighten anxiety
amongst the majority who will never develop recurrent
disease [142]. For patients who have evidence of metastatic
disease at time of surgery, it is nowadays generally accepted
that there is a survival beneﬁt to be gained if all gross
evidence of disease can be resected or at least debulked to
leave small-volume residual disease [148].
Most endometrial carcinomas are sporadic, but approxi-
mately 10% of cases have a hereditary basis [149–153]. Two
genetic models have been suggested in the development of
endometrial carcinoma: hereditary nonpolyposis colorectal
carcinoma (HNPCC) syndrome, also known as Lynch II
syndrome, and a predisposition for endometrial carcinoma
alone. Both are autosomal dominant inherited carcinoma
susceptibility syndrome caused by a germline mutation in
one of the deoxyribonucleic acid (DNA) mismatch repair
genes [153]. It is associated with early onset of carcinoma
(age younger than 50 years) and the development of multiple
carcinoma types, particularly colon and endometrial carci-
noma. Women with Lynch syndrome have a 40-60% risk of
endometrial carcinoma, which equals or exceeds their risk
of colorectal carcinoma. In addition, they have a 12% risk
of ovarian carcinoma. Despite limited information on the
eﬃcacy of surveillance in reducing endometrial and ovarian
carcinoma risk in women with Lynch syndrome, the current
gynecologic carcinoma screening guidelines include annual
endometrial sampling and transvaginal ultrasonography
beginning at age 30–35 years [154]. But the cost eﬀectiveness
of this screening has not been proven either. An alternative
approach is primary prevention by using a progestogen
device in utero, such as the Mirena IUCD. This merits full
evaluation [155].
In addition, risk-reducing surgery consisting of pro-
phylactic hysterectomy and bilateral salpingooophorectomy
should be oﬀered to women aged 35 years or older who
do not wish to preserve their fertility [154]. Schmeler
et al. reported a retrospective analysis of women with
known germline mutations associated withLynch syndrome.
Sixty-one participants underwent prophylactic hysterectomy
and were compared to over 200 matched controls with
similar mutations that did not have preventive surgery.
Endometrial carcinoma was eventually diagnosed in 33% of
the controls with no cases in the prophylactic surgery group
[156]. Pistorius et al. report detected asymptomatic muscle
invasive endometrial carcinoma in two of four women who
underwentprophylactichysterectomyafterrequiringsurgery
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In 2006 a multiinstitutional, matched case-control study
foundthatprophylactichysterectomywithbilateralsalpingo-
oophorectomy is an eﬀective primary preventive strategy
in women with HNPCC syndrome [156]. Based on these
observations, surgery as primary prevention for women at
high risk due to known germline lesions or history of Lynch
syndrome related malignancies may yield a meaningful
reduction in progression to endometrial carcinoma.
15. Summary
Endometrial carcinoma is a low-grade curable malignancy
and most patients who present with early disease have
excellent survival rate. Endometrial carcinoma remains a
management challenge, presenting with a full spectrum of
disease ranging from that with excellent prognosis and high
curability to aggressive disease with poor outcome. There are
many debates and controversies about optimal treatment for
women with diﬀerent staging endometrial carcinoma. How
do we summarize the current recommendations and how
do we proceed? Clinicians must balance delivering adequate
therapy while attempting to minimize treatment morbidity
and must always be weighed carefully.
Improved understanding of the mechanisms of carcino-
genesis may help identify molecular signatures that could
predict biologic behavior of individual disease presenta-
tions and discover potential molecular candidates for tar-
geted therapies. Total hysterectomy and bilateral salphingo-
oophorectomy is the primary operative procedure. Pelvic
lymhadenectomy is performed in most centers on thera-
peutic and prognostic grounds and to individualize adju-
vant treatment. Women with endometrial carcinoma can
be readily segregated intraoperatively into “low-risk” and
“high-risk” groups to better identify those women who
will most likely beneﬁt from thorough lymphadenectomy.
Postoperative irradiation is used to reduce pelvic and vaginal
recurrences in high risk cases. Treatment planning should
be conservative in order to reduce patients’ morbidity and
overtreatment while maintaining acceptable recurrence and
survival rates. Progression in diagnostic imaging, radiation
delivery systems, and systemic therapies potentially can
improve outcomes while minimizing morbidity. The avail-
ability of new hormonal and biological agents presents new
opportunities for therapy. Novel strategies for screening and
prevention also hold promise for reducing incidence and
mortality of this disease. The current evidence suggests that
there remain avenues to improve management and we need
to continue rigorous investigation to identify and implement
the best available practice. Research in the next ten years
shouldprovidevaluablenewstrategiesnotonlyfortreatment
but also for prevention.
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